Stress-induced Vascular Dysfunction: Evaluation of Endothelial Function in a Cohort of Patients With Takotsubo Syndrome
Launched by UNIVERSITY OF ZURICH · Nov 29, 2010
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
The aim of this prospective single-center study is to evaluate endothelial function, arterial compliance, sympathetic nervous activity at rest and after mental and physical stress, carotid atherosclerosis, oxidative stress parameters, quality of life and platelet adhesion in patients with Takotsubo Syndrome (apical ballooning syndrome/broken heart syndrome) and age-matched controls.
Gender
ALL
Eligibility criteria
- • Inclusion criteria: We plan to include male or female subjects, age 18-80 with a diagnosis of Takotsubo Syndrome (according to standard clinical criteria\[Strony, J., et al., Analysis of shear stress and hemodynamic factors in a model of coronary artery stenosis and thrombosis. Am J Physiol, 1993. 265(5 Pt 2): p. H1787-96.\]) in the last 10 years.
- • Moreover, patients matched to the Takotsubo patients for age and cardiovascular risk factors will be included in the control group.
- • All patients will signed an written informed consent
- Exclusion criteria:
- • Long acting nitrates, or PDE-5-Hemmer
- • Alcohol or drug abuse,
- • Malignancy (unless healed or remission \> 5 years)
- • Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)
- • Pulmonary Hypertension
- • Participation in another study within the last month
About University Of Zurich
The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, Zh, Switzerland
Patients applied
Trial Officials
Georg Noll, Prof MD
Principal Investigator
University Hospital Zurich, Division of Cardiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials